Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the Kennedy Institute demonstrate that the drug decitabine can boost regulatory T cell responses.

T cell © Shutterstock

A study by Dr I-Shu Huang and colleagues in Professor Richard Williams’s Group published in PNAS shows that decitabine, a drug currently approved for treatment of cancer patients, can boost regulatory T cells in animal models. As robust regulatory T cells have the capacity to suppress immune-driven inflammation, the findings offer a treatment pathway for chronic inflammatory diseases like rheumatoid arthritis (RA). 

Richard said: “RA is characterised by a deficit in fully functional regulatory T cells. But there is evidence that DNA-methylation inhibitors, used for treatment of cancer, increase regulatory T cell responses in patients. This led us to question whether short-term treatment of autoimmune arthritis with DNA methylation inhibitors could restore numbers of regulatory T cells, leading to long-term suppression of disease."  

Of three DNA methylation inhibitors tested in an animal model of rheumatoid arthritis, decitabine was the most effective, producing a sustained therapeutic effect. The researchers observed a profound and rapid decrease in numbers of pathogenic Th1 and Th17 cells in decitabine treated mice and an increase in numbers of regulatory T cells, particularly in the inflamed joint. 

“This study identifies a path toward resetting tolerance in autoimmune disease using a repurposed drug,” said Richard. “However, decitabine acts in a non-specific way and therefore is likely to have many off-target effects when used in a chronic disease like rheumatoid arthritis. Further research would aim to identify more selective epigenetic drugs to restore immune homeostasis.” 

Similar stories

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

Exploring the link between joint injury and osteoarthritis

A new study published in The Lancet Rheumatology shows potential ways to predict how likely someone is to develop osteoarthritis after a knee injury.

Small mechanical forces in immune cells measured at unprecedented sensitivity

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Vascular loss shown to be the primary hallmark of aging

New Research from the Kusumbe group at the Kennedy Institute of Rheumatology identifies vascular attrition, marked by pericyte to fibroblast differentiation, as a primary hallmark of aging and highlights organ-specific vascular changes with age.

Immunology preprint reviews launched in Nature Reviews Immunology

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.